Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay
The current number of drugs available for the treatment of Alzheimer’s disease (AD) is strongly limited and their benefit for therapy is given only in the early state of the disease. An effective therapy should affect those processes which mainly contribute to the neuronal decay. There hav...
Main Authors: | Max Holzer, Nico Schade, Ansgar Opitz, Isabel Hilbrich, Jens Stieler, Tim Vogel, Valentina Neukel, Moritz Oberstadt, Frank Totzke, Christoph Schächtele, Wolfgang Sippl, Andreas Hilgeroth |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-09-01
|
Series: | Molecules |
Subjects: | |
Online Access: | http://www.mdpi.com/1420-3049/23/9/2335 |
Similar Items
-
Electrostatics of Tau Protein by Molecular Dynamics
by: Tarsila G. Castro, et al.
Published: (2019-03-01) -
Phosphorylation and Dephosphorylation of Tau Protein During Synthetic Torpor
by: Marco Luppi, et al.
Published: (2019-06-01) -
Role of Tau Protein in Remodeling of Circadian Neuronal Circuits and Sleep
by: Mercedes Arnes, et al.
Published: (2019-11-01) -
Plasma tau complements CSF tau and P‐tau in the diagnosis of Alzheimer's disease
by: Silvia Fossati, et al.
Published: (2019-12-01) -
The Metamorphic Nature of the Tau Protein: Dynamic Flexibility Comes at a Cost
by: Jonathan J Sabbagh, et al.
Published: (2016-01-01)